Vol. 3 No. 1 (2026)

Research Articles

Lymphocyte subset distribution can predict the efficacy of first-line treatment in patients with non-Hodgkin lymphoma.

Published 2026-01-31

  • Yumei Huang
    • ,
  • Zhenjun Tan
    • ,
  • Hongyu Deng
    • ,
  • Hongjun Huang
    • ,
  • Faqing Tang

Yumei Huang
Xiangya Hospital Central South University image/svg+xml

Zhenjun Tan
AmoyDx Biotechnology, Xiamen, Fujian, China

Hongyu Deng
Xiangya Hospital Central South University image/svg+xml

Hongjun Huang
Xiangya Hospital Central South University image/svg+xml

Faqing Tang
Xiangya Hospital Central South University image/svg+xml

Abstract

Objective: To explore the relationship between peripheral blood lymphocyte subsets and diffuse large B-cell lymphoma ( DBL) . large B-cell lymphoma , DLBCL and nasal NK/T-cell lymphoma (NK/T-cell) To investigate the relationship between first-line treatment efficacy and predictive biomarkers for DLBCL (Diagnosis Related-Brain Colopathy) and nasal ENKTL (Enzyme-Lung Cell Toxic Leukoma). Methods: The basic pathological characteristics of 110 patients diagnosed with DLBCL or nasal ENKTL were analyzed, and the efficacy of first-line treatment regimens was evaluated. The correlations between peripheral blood lymphocyte subsets, tumor-specific growth factor ( TSGF ) , lactate dehydrogenase ( LDH ) , and Ki67 with the efficacy of first-line treatment for DLBCL and nasal ENKTL were also examined. P < 0.05 was considered statistically significant. Results: 1. DLBCL was more predominantly diagnosed at an advanced stage (III-IV), while nasal ENKTL was more predominantly diagnosed at an early stage (I) (P = 0.000 ). DLBCL was primarily treated with CHOP-containing regimens, while nasal ENKTL was primarily treated with GELOXD regimens (P = 0.000 ). DLBCL was predominantly associated with partial remission (PR), while nasal ENKTL was predominantly associated with complete remission (CR). Nasal ENKTL had a better prognosis (P = 0.005 ). 2. Stage, CD8 + T lymphocyte ratio , and LDH were independent risk factors for the efficacy of first-line treatment of DLBCL (higher levels indicate worse efficacy); while stage and T lymphocyte ratio were risk factors for the efficacy of first-line treatment with nasal ENKTL (higher levels indicate worse efficacy). Conclusion: The distribution of peripheral blood lymphocyte subsets is closely related to the efficacy of first-line treatment for DLBCL and nasal ENKTL. By detecting the distribution of peripheral blood lymphocyte subsets before treatment, the efficacy of first-line treatment for DLBCL and nasal ENKTL can be predicted, thereby guiding physicians to adjust treatment plans.

Keywords

Non-Hodgkin's lymphoma, Diffuse large B-cell lymphoma, Nasal NK/T-cell lymphoma, Lymphocyte subsets, Flow cytometry, Tumor-specific growth factor ( TSGF ), Lactate dehydrogenase ( LDH ), Ki67

PDF

References

  1. Silkenstedt E, Salles G, Campo E, Dreyling M. B-cell non-Hodgkin lymphomas. Lancet. 2024 May 4;403(10438):1791-1807. doi: 10.1016/S0140-6736(23)02705-8. Epub 2024 Apr 10. PMID: 38614113.
  2. Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma[J]. Lancet. 2017, 390(10091):298-310.doi: 10.1016/S0140-6736(16)32407-2. Epub 2017 Jan 31. PMID: 28153383.
  3. [A1] KHOURY J D, SOLARY E, ABLA O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/ dendritic neoplasms[J]. Leukemia, 2022, 36(7): 1703-1719.
  4. [A 2] ZHANG Yue, YU Liqian, WANG Rang, et al. Nasal-type extranodal natural killer/T-cell lymphoma recurrence at penile glans masquerading urinary contamination on 18 F-FDG PET/CT[J]. Clinical Nuclear Medicine, 2023, 48(9): 812-814.
  5. [A3]宋晓昕,郭丽改,杨蕾蕾,李媛,刘江英,侯君,苗杰.头颈部淋巴瘤亚型构成比及病理形态单中心研究[J].河北医药,2024,46(6):844-848.DOI:10.3969/j.issn.1002-7386.2024.06.009.
  6. [A4]高旭栋,李安,赵博,李岚.鼻腔鼻窦NK/T细胞淋巴瘤与弥漫大B细胞淋巴瘤的临床及影像学特征比较[J].中国实用医刊,2024,51(1):6-9.DOI:10.3760/cma.j.cn115689-20231021-03469.
  7. [A7]Hao,Zhang,Yan,Li,Gang,Liu,Xin,Chen.Expression analysis of lymphocyte subsets and lymphocyte-to-monocyte ratio: reveling immunosuppression and chronic inflammation in breast cancer.[J].Journal of cancer research and clinical oncology,2024,150(1):28.DOI:10.1007/s00432-023-05508-1.
  8. [A5]史恩红,张东利,李兰兰,张春东.胸苷激酶1与恶性肿瘤特异生长因子在晚期结直肠癌患者中的表达及临床意义[J].实用检验医师杂志,2023,15(3):274-277.DOI:10.3969/j.issn.1674-7151.2023.03.013.
  9. [A6]姜晨霞,章小霞,张曙,王燕.肝细胞癌中Semaphorin5A及Ki-67的表达及其临床意义[J].临床与实验病理学杂志,2023,39(2):151-156.DOI:10.13315/j.cnki.cjcep.2023.02.005.
  10. 石远凯,秦燕,陈海珠,等.中国淋巴瘤治疗指南（2023年版）[J].中国肿瘤临床与康复,2023,30(01):2-39.DOI:10.13455/j.cnki.cjcor.113494-20230118-0032.
  11. 顾天翔,刘红,杨力.《淋巴瘤诊断与治疗》出版:难治性弥漫大B细胞淋巴瘤治疗的新进展研究[J].介入放射学杂志,2023,32(2):后插5.DOI:10.3969/j.issn.1008-794X.2023.02.029.
  12. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma[J]. Nat Med, 2015, 21(8): 922-926. DOI: 10.1038/nm.3884.
  13. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project [J]. Blood, 2009, 113(17): 3931-3937. DOI ：10.1182/blood-2008-10-185256.
  14. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, Yau CC, Kwong YL. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004 Jan 1;103(1):216-21. doi: 10.1182/blood-2003-05-1401. Epub 2003 Aug 21. PMID: 12933580.
  15. Li JW, Li YJ, Zhong MZ, Liu XL, Li J, Li KL, Liu XY, Zhou F, OuYang Z, Sun ZY, Huang LJ, He JQ, Zhou H, Yi PY. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study. Eur J Haematol. 2018 Mar;100(3):247-256. doi: 10.1111/ejh.13004. Epub 2018 Jan 11. PMID: 29194798.
  16. 张波,陈明贤,李红军, 等.外周血淋巴细胞亚群检测在肺癌诊断和治疗中的应用[J].中国卫生检验杂志,2018,28(6):676-678,681.
  17. 兰炎根,陈舒华,李嘉, 等.淋巴细胞亚群在鼻咽癌高癌家系外周血中的临床意义[J].中国肿瘤外科杂志,2020,12(6):556-559. DOI:10.3969/j.issn.1674-4136.2020.06.014.
  18. 刘云鹤,于建春,贾英杰, 等.508例恶性肿瘤患者外周血淋巴细胞亚群分析[J].国际肿瘤学杂志,2016,43(6):405-408. DOI:10.3760/cma.j.issn.1673-422X.2016.06.002.
  19. Hao,Zhang,Yan,Li,Gang,Liu,Xin,Chen.Expression analysis of lymphocyte subsets and lymphocyte-to-monocyte ratio: reveling immunosuppression and chronic inflammation in breast cancer.[J].Journal of cancer research and clinical oncology,2024,150(1):28.DOI:10.1007/s00432-023-05508-1.
  20. 黄晓路,罗剑,何远春.基于T淋巴细胞亚群构建原发性肝癌患者氩氦刀冷冻消融术后残癌风险预测模型[J].中国肿瘤外科杂志,2024,16(2):148-152.DOI:10.3969/j.issn.1674-4136.2024.02.009.
  21. 王馨焱,刘晓玲,贾军梅.淋巴细胞亚群在胃癌免疫检查点抑制剂治疗中的研究进展[J].癌变.畸变.突变,2024,36(1):80-83.DOI:10.3969/j.issn.1004-616x.2024.01.014.
  22. Ling,Yi,Ziwei,Xu,Tianyu,Ma,Chong,Wang,Panjian,Wei,Bo,Xiao,Hongtao,Zhang,Nanying,Che,Zhidong,Liu,Yi,Han.T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.[J].Cancer immunology, immunotherapy : CII,2024,73(6):99.DOI:10.1007/s00262-024-03687-5.
  23. 谢丹娜,李英华,陈晓静,等. 鼻腔NK/T细胞淋巴瘤患者的生存及预后分析[J]. 中国实验血液学杂志,2020,28(2):507-511. DOI:10.19746/j.cnki.issn1009-2137.2020.02.025.